Search

Your search keyword '"Leppä, Sirpa"' showing total 558 results
Start Over Author "Leppä, Sirpa"
558 results on '"Leppä, Sirpa"'

51. The EHA Research Roadmap: Malignant Lymphoid Diseases

Author

Dreyling, Martin, primary, André, Marc, additional, Gökbuget, Nicola, additional, Tilly, Hervé, additional, Jerkeman, Mats, additional, Gribben, John, additional, Ferreri, Andrés, additional, Morel, Pierre, additional, Stilgenbauer, Stephan, additional, Fox, Christopher, additional, Maria Ribera, José, additional, Zweegman, Sonja, additional, Aurer, Igor, additional, Bödör, Csaba, additional, Burkhardt, Birgit, additional, Buske, Christian, additional, Dollores Caballero, Maria, additional, Campo, Elias, additional, Chapuy, Bjoern, additional, Davies, Andrew, additional, de Leval, Laurence, additional, Doorduijn, Jeanette, additional, Federico, Massimo, additional, Gaulard, Philippe, additional, Gay, Francesca, additional, Ghia, Paolo, additional, Grønbæk, Kirsten, additional, Goldschmidt, Hartmut, additional, Kersten, Marie-Jose, additional, Kiesewetter, Barbara, additional, Landman-Parker, Judith, additional, Le Gouill, Steven, additional, Lenz, Georg, additional, Leppä, Sirpa, additional, Lopez-Guillermo, Armando, additional, Macintyre, Elizabeth, additional, Mantega, Maria Victoria Mateos, additional, Moreau, Philippe, additional, Moreno, Carol, additional, Nadel, Bertrand, additional, Okosun, Jessica, additional, Owen, Roger, additional, Pospisilova, Sarka, additional, Pott, Christiane, additional, Robak, Tadeusz, additional, Spina, Michelle, additional, Stamatopoulos, Kostas, additional, Stary, Jan, additional, Tarte, Karin, additional, Tedeschi, Allessandra, additional, Thieblemont, Catherine, additional, Trappe, Ralf Ulrich, additional, Trümper, Lorenz H., additional, and Salles, Gilles, additional

Published
2022
Full Text
View/download PDF

52. The EHA Research Roadmap: Malignant Lymphoid Diseases.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Dreyling, Martin, André, Marc, Gökbuget, Nicola, Tilly, Hervé, Jerkeman, Mats, Gribben, John, Ferreri, Andrés, Morel, Pierre, Stilgenbauer, Stephan, Fox, Christopher, Maria Ribera, José, Zweegman, Sonja, Aurer, Igor, Bödör, Csaba, Burkhardt, Birgit, Buske, Christian, Dollores Caballero, Maria, Campo, Elias, Chapuy, Bjoern, Davies, Andrew, de Leval, Laurence, Doorduijn, Jeanette, Federico, Massimo, Gaulard, Philippe, Gay, Francesca, Ghia, Paolo, Grønbæk, Kirsten, Goldschmidt, Hartmut, Kersten, Marie-Jose, Kiesewetter, Barbara, Landman-Parker, Judith, Le Gouill, Steven, Lenz, Georg, Leppä, Sirpa, Lopez-Guillermo, Armando, Macintyre, Elizabeth, Mantega, Maria Victoria Mateos, Moreau, Philippe, Moreno, Carol, Nadel, Bertrand, Okosun, Jessica, Owen, Roger, Pospisilova, Sarka, Pott, Christiane, Robak, Tadeusz, Spina, Michelle, Stamatopoulos, Kostas, Stary, Jan, Tarte, Karin, Tedeschi, Allessandra, Thieblemont, Catherine, Trappe, Ralf Ulrich, Trümper, Lorenz H, Salles, Gilles, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Dreyling, Martin, André, Marc, Gökbuget, Nicola, Tilly, Hervé, Jerkeman, Mats, Gribben, John, Ferreri, Andrés, Morel, Pierre, Stilgenbauer, Stephan, Fox, Christopher, Maria Ribera, José, Zweegman, Sonja, Aurer, Igor, Bödör, Csaba, Burkhardt, Birgit, Buske, Christian, Dollores Caballero, Maria, Campo, Elias, Chapuy, Bjoern, Davies, Andrew, de Leval, Laurence, Doorduijn, Jeanette, Federico, Massimo, Gaulard, Philippe, Gay, Francesca, Ghia, Paolo, Grønbæk, Kirsten, Goldschmidt, Hartmut, Kersten, Marie-Jose, Kiesewetter, Barbara, Landman-Parker, Judith, Le Gouill, Steven, Lenz, Georg, Leppä, Sirpa, Lopez-Guillermo, Armando, Macintyre, Elizabeth, Mantega, Maria Victoria Mateos, Moreau, Philippe, Moreno, Carol, Nadel, Bertrand, Okosun, Jessica, Owen, Roger, Pospisilova, Sarka, Pott, Christiane, Robak, Tadeusz, Spina, Michelle, Stamatopoulos, Kostas, Stary, Jan, Tarte, Karin, Tedeschi, Allessandra, Thieblemont, Catherine, Trappe, Ralf Ulrich, Trümper, Lorenz H, and Salles, Gilles

Published
2022

53. The EHA Research Roadmap:Malignant Lymphoid Diseases

Author

Dreyling, Martin, André, Marc, Gökbuget, Nicola, Tilly, Hervé, Jerkeman, Mats, Gribben, John, Ferreri, Andrés, Morel, Pierre, Stilgenbauer, Stephan, Fox, Christopher, Maria Ribera, José, Zweegman, Sonja, Aurer, Igor, Bödör, Csaba, Burkhardt, Birgit, Buske, Christian, Dollores Caballero, Maria, Campo, Elias, Chapuy, Bjoern, Davies, Andrew, De Leval, Laurence, Doorduijn, Jeanette, Federico, Massimo, Gaulard, Philippe, Gay, Francesca, Ghia, Paolo, Grønbæk, Kirsten, Goldschmidt, Hartmut, Kersten, Marie Jose, Kiesewetter, Barbara, Landman-Parker, Judith, Le Gouill, Steven, Lenz, Georg, Leppä, Sirpa, Lopez-Guillermo, Armando, Macintyre, Elizabeth, Mantega, Maria Victoria Mateos, Moreau, Philippe, Moreno, Carol, Nadel, Bertrand, Okosun, Jessica, Owen, Roger, Pospisilova, Sarka, Pott, Christiane, Robak, Tadeusz, Spina, Michelle, Stamatopoulos, Kostas, Stary, Jan, Tarte, Karin, Tedeschi, Allessandra, Thieblemont, Catherine, Trappe, Ralf Ulrich, Trümper, Lorenz H., Salles, Gilles, Dreyling, Martin, André, Marc, Gökbuget, Nicola, Tilly, Hervé, Jerkeman, Mats, Gribben, John, Ferreri, Andrés, Morel, Pierre, Stilgenbauer, Stephan, Fox, Christopher, Maria Ribera, José, Zweegman, Sonja, Aurer, Igor, Bödör, Csaba, Burkhardt, Birgit, Buske, Christian, Dollores Caballero, Maria, Campo, Elias, Chapuy, Bjoern, Davies, Andrew, De Leval, Laurence, Doorduijn, Jeanette, Federico, Massimo, Gaulard, Philippe, Gay, Francesca, Ghia, Paolo, Grønbæk, Kirsten, Goldschmidt, Hartmut, Kersten, Marie Jose, Kiesewetter, Barbara, Landman-Parker, Judith, Le Gouill, Steven, Lenz, Georg, Leppä, Sirpa, Lopez-Guillermo, Armando, Macintyre, Elizabeth, Mantega, Maria Victoria Mateos, Moreau, Philippe, Moreno, Carol, Nadel, Bertrand, Okosun, Jessica, Owen, Roger, Pospisilova, Sarka, Pott, Christiane, Robak, Tadeusz, Spina, Michelle, Stamatopoulos, Kostas, Stary, Jan, Tarte, Karin, Tedeschi, Allessandra, Thieblemont, Catherine, Trappe, Ralf Ulrich, Trümper, Lorenz H., and Salles, Gilles

Abstract

In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 iming to highlight achievements in the diagnostics and treatment of blood disorders and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1 to 2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European hematology research. The 11 EHA Research Roadmap sections include Normal Hematopoiesis; Malignant Lymphoid Diseases; Malignant Myeloid Diseases; Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Disorders; Transfusion Medicine; Infections in Hematology; Hematopoietic Stem Cell Transplantation; CAR-T and Other Cellbased Immune Therapies; and Gene Therapy.

Published
2022

55. Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)

Author

Dickinson, Michael, primary, Carlo-Stella, Carmelo, additional, Morschhauser, Franck, additional, Patel, Krish, additional, Khan, Cyrus, additional, Bartlett, Nancy L., additional, Iacoboni, Gloria, additional, Hertzberg, Mark, additional, Leppä, Sirpa, additional, Van Den Neste, Eric, additional, Tani, Monica, additional, Cartron, Guillaume, additional, Salar, Antonio, additional, Perez-Callejo, David, additional, Lundberg, Linda, additional, Relf, James, additional, Clark, Emma, additional, Humphrey, Kathryn, additional, and Hutchings, Martin, additional

Published
2021
Full Text
View/download PDF

58. Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and 1H-MR spectroscopy compared with histology (subgroup in the RAXO trial)

Author

Uutela, A., primary, Ovissi, A., additional, Hakkarainen, A., additional, Ristimäki, A., additional, Lundbom, N., additional, Kallio, R., additional, Soveri, L.M., additional, Salminen, T., additional, Ålgars, A., additional, Halonen, P., additional, Ristamäki, R., additional, Nordin, A., additional, Blanco Sequeiros, R., additional, Rinta-Kiikka, I., additional, Lantto, E., additional, Virtanen, J., additional, Pääkkö, E., additional, Liukkonen, E., additional, Saunavaara, J., additional, Ryymin, P., additional, Lammentausta, E., additional, Osterlund, P., additional, Isoniemi, H., additional, Mäkisalo, Heikki, additional, Huuhtanen, Riikka, additional, Kosunen, Juhani, additional, Leppä, Sirpa, additional, Bono, Petri, additional, Mattson, Johanna, additional, Österlund, Emerik, additional, Penttinen, Heidi, additional, Mäkelä, Siru, additional, Carpén, Olli, additional, Timonen, Marjut, additional, Lehtomäki, Kaisa, additional, Salminen, Veera, additional, Paunu, Niina, additional, Vornanen, Martine, additional, Lasse, Nieminen, additional, Heervä, Eetu, additional, Korkeila, Eija, additional, Sutinen, Eija, additional, Lavonius, Maija, additional, Sundström, Jari, additional, Mäkinen, Markus, additional, and Poussa, Tuija, additional

Published
2021
Full Text
View/download PDF

59. Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Author

Falchi, Lorenzo, Carlo-Stella, Carmelo, Morschhauser, Franck, Dickinson, Michael, Bachy, Emmanuel, Cartron, Guillaume, Khan, Cyrus, Tani, Monica, Martinez-Lopez, Joaquin, Bartlett, Nancy L., Salar, Antonio, Brody, Joshua, Leppä, Sirpa, Berthier, Aurelien, Kallemeijn, Martine, Relf, James, Chohan, Saibah, Lundberg, Linda, and Hutchings, Martin

Published
2023
Full Text
View/download PDF

63. Kiveslymfooma

Author

Pollari, Marjukka, Mannisto, Susanna, Vähämurto, Pauli, Leppä, Sirpa, Tampere University, and Syövänhoidon vastuualue

Subjects
3122 Syöpätaudit
Abstract

Kiveslymfooma on harvinainen, aggressiivinen lymfooma-alatyyppi. Se on kuitenkin tavallisin iäkkäiden miesten kivessyöpä ja histologialtaan yleisimmin diffuusi suurisoluinen B-solulymfooma. Biologisesti kiveksen diffuusi suurisoluinen B-solulymfooma eroaa primaarisesti imusolmukealueilla esiintyvästä tautimuodosta ja muistuttaa keskushermoston diffuusia suurisoluista B-solulymfoomaa. Sillä on taipumus uusiutua muihin imusolmukealueiden ulkopuolisiin elimiin, erityisesti vastakkaiseen kivekseen ja keskushermostoon. Kiveslymfooman hoito koostuu sairaan kiveksen poistosta, sen jälkeisestä solunsalpaajien ja vasta-aineen yhdistelmähoidosta, keskushermostoon kohdennetusta solunsalpaajahoidosta sekä vastakkaisen kiveksen ehkäisevästä poistosta tai sädehoidosta. Taudin ennuste on nykyisin kohtalaisen hyvä. Uusia hoitomuotoja kaivataan erityisesti iäkkäämpien, hauraiden potilaiden hoitoon. publishedVersion

Published
2021

64. Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma

Author

Vajavaara, Heli, Mortensen, Julie Bondgaard, Leivonen, Suvi-Katri, Hansen, Ida Monrad, Ludvigsen, Maja, Holte, Harald, Jørgensen, Judit, Bjerre, Mette, d’Amore, Francesco, Leppä, Sirpa, HUS Comprehensive Cancer Center, Department of Oncology, Sirpa Marianne Leppä / Principal Investigator, ATG - Applied Tumor Genomics, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki University Hospital Area, Digital Precision Cancer Medicine (iCAN), and Clinicum

Subjects
3122 Cancers, mental disorders, diffuse large B-cell lymphoma, soluble PD-1, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, soluble PD-L1, survival, Article
Abstract

Interaction of checkpoint receptor programmed death 1 (PD-1) with its ligand 1 (PD-L1) downregulates T cell effector functions and thereby leads to tumor immune escape. Here, we aimed to determine the clinical significance of soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1) in patients with diffuse large B-cell lymphoma (DLBCL). We included 121 high-risk DLBCL patients treated in the Nordic NLG-LBC-05 trial with dose-dense immunochemotherapy. sPD-1 and sPD-L1 levels were measured from serum samples collected prior to treatment, after three immunochemotherapy courses, and at the end of therapy. sPD-1 and sPD-L1 levels were the highest in pretreatment samples, declining after three courses, and remaining low post-treatment. Pretreatment sPD-1 levels correlated with the quantities of PD1+ T cells in tumor tissue and translated to inferior survival, while no correlation was observed between sPD-L1 levels and outcome. The relative risk of death was 2.9-fold (95% CI 1.12&ndash, 7.75, p = 0.028) and the risk of progression was 2.8-fold (95% CI 1.16&ndash, 6.56, p = 0.021) in patients with high pretreatment sPD-1 levels compared to those with low levels. In conclusion, pretreatment sPD-1 level is a predictor of poor outcome after dose-dense immunochemotherapy and may be helpful in further improving molecular risk profiles in DLBCL.

Published
2021
Full Text
View/download PDF

65. Testicular diffuse large b-cell lymphoma—clinical, molecular, and immunological features

Author

Pollari, Marjukka, Leivonen, Suvi Katri, Leppä, Sirpa, Tampere University, and Department of Oncology

Subjects
immune system diseases, hemic and lymphatic diseases, 3122 Cancers
Abstract

Primary testicular lymphoma is a rare lymphoma entity, yet it is the most common testicular malignancy among elderly men. The majority of the cases represent non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with aggressive clinical behavior and a relatively high relapse rate. Due to the rareness of the disease, no randomized clinical trials have been conducted and the currently recognized standard of care is based on retrospective analyses and few phase II trials. During recent years, the tumor microenvironment (TME) and tumor-related immunity have been the focus of many tumor biology studies, and the emergence of targeted therapies and checkpoint inhibitors has significantly modulated the field of cancer therapies. Testicular DLBCL (T-DLBCL) is presented in an immune-privileged site of the testis, and the roles of NF-κB pathway signaling, 9p24.1 aberrations, and tumor-infiltrating immune cells, especially immune checkpoint expressing lymphocytes and macrophages, seem to be unique compared to other lymphoma entities. Preliminary data on the use of immune checkpoint inhibitors in the treatment of T-DLBCL are promising and more studies are ongoing. publishedVersion

Published
2021

66. Kantasolusiirrot - soluterapia murroksessa

Author

Vettenranta, Kim, Leppä, Sirpa, Janes, Rita, Niittyvuopio, Riitta, Salmenniemi, Urpu, Taskinen, Mervi, Ryhänen, Samppa, Keränen, Mikko, Jahnukainen, Kirsi, Itälä-Remes, Maija, HUS Lasten ja nuorten sairaudet, Lastentautien yksikkö, Lastenklinikka, Syöpätautien osasto, HUS Syöpäkeskus, Hematologian yksikkö, and Clinicum

Subjects
Adult, Leukemia, Lymphoma, 3122 Syöpätaudit, Transplantation, Heterologous, Transplants, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Transplantation, Autologous, Hematologic Diseases, +adverse effects, Graft vs Host Reaction, Immune System Diseases, +therapy, Transplantation Tolerance, Child, Stem Cell Transplantation
Abstract

Vertaisarvioitu. Kantasolusiirrot ovat vakiinnuttaneet asemansa hematologisten syöpätautien sekä synnynnäisten luuytimen ja immuunijärjestelmän toiminnanvajavuustilojen hoidossa. Kehitys on viiden vuosikymmenen aikana mahdollistanut luovuttajakirjon laajentamisen, ikääntyneempien potilaiden hoidon sekä hoitotulosten paranemisen. Aikuispotilaiden allogeenisen siirron aiheena on edelleen pääasiassa leukemia, mutta lapsipotilaiden osalta yhä enemmän myös immuunijärjestelmän ja verenmuodostuksen häiriöt. Autologisen kantasolutuen käyttö puolestaan painottuu aikuispotilaiden lymfoomien sekä myelooman hoitoon, ja sen käyttö lapsipotilaiden hoidossa on verraten vähäistä. Käänteishyljintä muodostaa edelleen keskeisen ongelman. Kantasolusiirto edeltävine hoitoineen aiheuttaa pitkäaikaishaittavaikutuksia ja elinikäisen seurantatarpeen. Uudet immunologisen täsmähoidon muodot ovat tulleet vastikään kliiniseen käyttöön, mutta kantasolusiirrot säilyttänevät asemansa erityisesti leukemian hoidossa vielä nähtävillä olevassa tulevaisuudessa.

Published
2021

67. Lymfoomahoitojen jälkeiset pitkäaikaishaitat, niiden ehkäisy ja seuranta

Author

Sunela, Kaisa, Leppä, Sirpa, Kuittinen, Outi, Tinkanen, Helena, Tuohinen, Suvi, Schmitt, Florence, Korkeila, Eija, Helsingin yliopisto, Syöpätautien osasto, Helsingin yliopisto, HUS Sydän- ja keuhkokeskus, Syöpätautien osasto, HUS Syöpäkeskus, Helsingin yliopisto, HUS Sydän- ja keuhkokeskus, Clinicum, Sisätautien osasto, Kardiologian yksikkö, Tampere University, Syövänhoidon vastuualue, Kliininen lääketiede, and Naistentautien ja synnytysten vastuualue

Subjects
3121 Yleislääketiede, sisätaudit ja muut kliiniset lääketieteet, 3122 Syöpätaudit, 3121 Sisätaudit, 3126 Kirurgia, anestesiologia, tehohoito, radiologia
Abstract

Vertaisarvioitu. English summary. Myöhäishaitat ovat edelleen tavallisia lymfoomahoitojen jälkeen, ja niiden riski jatkuu koko elämän. Vaikka hoitojen kehittyminen on vähentänyt haittoja, varsinkin sekundaarisyövät sekä sydän- ja verisuonitaudit aiheuttavat ylikuolleisuutta. Perusterveydenhuollon tuleekin olla tietoinen mahdollisista ongelmista ja hoitaa riskitekijöitä tehokkaasti. Psykososiaalisten haittojen ehkäisemiseksi tarvitaan lisää tukea potilaille. Suomen Lymfoomaryhmä on tehnyt suosituksen myöhäishaittojen ehkäisemiseksi ja seuraamiseksi.

Published
2020

68. The DLBCL90 gene‐expression assay identifies double‐hit lymphomas with high sensitivity in patients from two phase II clinical trials with high‐risk diffuse large B‐cell lymphoma

Author

Isaksen, Kathrine T., primary, Beiske, Klaus, additional, Smeland, Erlend B., additional, Jørgensen, Judit, additional, Brodtkorb, Marianne, additional, Myklebust, June Helen, additional, Jerkeman, Mats, additional, Meriranta, Leo, additional, Karjalainen‐Lindsberg, Marja‐Liisa, additional, Leppä, Sirpa, additional, Scott, David W., additional, Holte, Harald, additional, and Blaker, Yngvild Nuvin, additional

Published
2020
Full Text
View/download PDF

73. Immunogenomic Landscape of Hematological Malignancies

Author

Dufva, Olli, primary, Pölönen, Petri, additional, Brück, Oscar, additional, Keränen, Mikko A.I., additional, Klievink, Jay, additional, Mehtonen, Juha, additional, Huuhtanen, Jani, additional, Kumar, Ashwini, additional, Malani, Disha, additional, Siitonen, Sanna, additional, Kankainen, Matti, additional, Ghimire, Bishwa, additional, Lahtela, Jenni, additional, Mattila, Pirkko, additional, Vähä-Koskela, Markus, additional, Wennerberg, Krister, additional, Granberg, Kirsi, additional, Leivonen, Suvi-Katri, additional, Meriranta, Leo, additional, Heckman, Caroline, additional, Leppä, Sirpa, additional, Nykter, Matti, additional, Lohi, Olli, additional, Heinäniemi, Merja, additional, and Mustjoki, Satu, additional

Published
2020
Full Text
View/download PDF

76. STAT3 Mutation Is Associated with STAT3 Activation in CD30+ ALK− ALCL

Author

Andersson, Emma I., primary, Brück, Oscar, additional, Braun, Till, additional, Mannisto, Susanna, additional, Saikko, Leena, additional, Lagström, Sonja, additional, Ellonen, Pekka, additional, Leppä, Sirpa, additional, Herling, Marco, additional, Kovanen, Panu E., additional, and Mustjoki, Satu, additional

Published
2020
Full Text
View/download PDF

78. Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

Author

Dreyling, Martin, primary, Santoro, Armando, additional, Mollica, Luigina, additional, Leppä, Sirpa, additional, Follows, George, additional, Lenz, Georg, additional, Kim, Won Seog, additional, Nagler, Arnon, additional, Dimou, Maria, additional, Demeter, Judit, additional, Özcan, Muhit, additional, Kosinova, Marina, additional, Bouabdallah, Krimo, additional, Morschhauser, Franck, additional, Stevens, Don A., additional, Trevarthen, David, additional, Munoz, Javier, additional, Rodrigues, Liana, additional, Hiemeyer, Florian, additional, Miriyala, Ashok, additional, Garcia‐Vargas, Jose, additional, Childs, Barrett H., additional, and Zinzani, Pier Luigi, additional

Published
2020
Full Text
View/download PDF

79. Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

Author

Li, Xiang, primary, Kositsky, Rachel, primary, Reddy, Anupama, primary, Love, Cassandra, primary, Naresh, Kikkeri, primary, Koff, Jean L., primary, Nystrand, Ilja, primary, Leppä, Sirpa, primary, Pasanen, Annika, primary, Karjalainen-Lindsberg, Marja-Liisa, primary, Dunkel, Johannes, primary, Kovanen, Panu, primary, Qin, Qiu, primary, Bhagat, Govind, primary, Leeman-Neill, Rebecca J, primary, Goswami, Rashmi S., primary, Wildeman, Sarah, primary, Delabie, Jan, primary, Burack, Richard, primary, Evans, Andrew G, primary, Amador, Catalina, primary, Yuan, Ji, primary, Qureishi, Hina Naushad, primary, Li, Shaoying, primary, Xu, Jie, primary, Yin, C. Cameron, primary, Gang, Anne Ortved, primary, Norgaard, Peter H., primary, Pedersen, Mette Ø, primary, Chan, Jason Yongsheng, primary, Cheah, Daryl Ming Zhe, primary, Ong, Shin Yeu, primary, Cheng, Chee Leong, primary, Lee, Lianne, primary, Paulua, Felik, primary, Ondrejka, Sarah L., primary, Hsi, Eric D., primary, Czader, Magdalena, primary, Wang, Lin, primary, Landis, Amber, primary, Churnetski, Michael C., primary, Jaye, David L., primary, Flowers, Christopher R., primary, McCall, Chad M., primary, Neff, Jadee, primary, McKinney, Matthew S., primary, Fedoriw, Yuri, primary, Powers, Eric, primary, Montgomery, Nathan D, primary, Bogusz, Agata M., primary, Stafford Hintz, Andrea, primary, Kovach, Alexandra E., primary, Reddy, Nishitha, primary, Thompson Arildsen, Mary Ann, primary, Mason, Emily F, primary, Juskevicius, Ridas, primary, Choi, William, primary, Au-Yeung, Rex, primary, Tse, Eric, primary, Sarno, Vincent, primary, Chadburn, Amy, primary, Lopez, Rafael, primary, Chapman, Jennifer R, primary, Behdad, Amir, primary, Goldschmidt, Neta, primary, Goodlad, John, primary, Burton, Cathy, primary, Pillai, Raju, primary, Louissaint, Abner, primary, Soliman, Dina Sameh, primary, Panea, Razvan, primary, Dave, Tushar, primary, Xiong, Barbara, primary, Smith, Eileen, primary, and Dave, Sandeep, primary

Published
2019
Full Text
View/download PDF

80. Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Author

Zinzani, Pier Luigi, primary, Santoro, Armando, additional, Mollica, Luigina, additional, Leppä, Sirpa, additional, Follows, George A, additional, Lenz, Georg, additional, Kim, Won Seog, additional, Nagler, Arnon, additional, Panayiotidis, Panayiotis, additional, Demeter, Judit, additional, Morschhauser, Franck, additional, Munoz, Javier, additional, Miriyala, Ashok, additional, Benson, Alice, additional, Garcia-Vargas, Jose, additional, Childs, Barrett H, additional, and Dreyling, Martin, additional

Published
2019
Full Text
View/download PDF

82. Diffuusin suurisoluisen B-solulymfooman nykyhoito

Author

Leppä, Sirpa, Meriranta, Leo, Pasanen, Annika, Jyrkkiö, Sirkku, Syöpätautien osasto, HUS Syöpäkeskus, Tutkimusohjelmayksikkö, and Helsingin yliopisto

Subjects
3122 Syöpätaudit
Abstract

Teema : Hematologiset syövät. English summary

Published
2019

87. Syövän immunologinen täsmähoito geneettisesti muokatuilla T-soluilla

Author

Korhonen, Matti, Keränen, Mikko, Vettenranta, Kim, Leppä, Sirpa, Ylä-Herttuala, Seppo, Porkka, Kimmo, Hematologian yksikkö, Clinicum, Syöpätautien osasto, Helsingin yliopisto, Lastentautien yksikkö, Lastenklinikka, Doctoral Programme in Drug Research, HUS Lasten ja nuorten sairaudet, and HUS Syöpäkeskus

Subjects
3122 Syöpätaudit, GeneralLiterature_INTRODUCTORYANDSURVEY, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract

English summary

Published
2018

88. Syöpäpotilaan hedelmällisyyden säilyttäminen

Author

Ranta, Varpu, Leppä, Sirpa, Mattson, Johanna, Naistenklinikka, Clinicum, Syöpätautien osasto, Helsingin yliopisto, and HUS Syöpäkeskus

Subjects
+drug therapy, Cryopreservation, Radiotherapy, 3122 Syöpätaudit, Ovary, +radiotherapy, Fertility Preservation, Antineoplastic Agents, Embryo, Mammalian, Spermatozoa, +adverse effects, 3123 Naisten- ja lastentaudit, Infertility, Neoplasms, +prevention & control, +etiology, Infertility, Female, Antineoplastic Agents, Alkylating, Infertility, Male, Ovum
Abstract

• Monet syövän hoidot heikentävät hedelmällisyyttä. Hoitojen vaikutuksesta on tärkeää antaa neuvontaa. • Naispotilaan hedelmällisyys ja mahdollisuus sen säilyttämiseen arvioidaan yksilöllisesti. Hedelmällisyyden säilyttämiseen tähtääviä hoitoja tarjotaan niitä toivoville. • Miehille on hyvä tarjota mahdollisuus siittiöiden pakastamiseen aina, kun suunnitellaan siittiötuotantoon mahdollisesti vaikuttavaa hoitoa.

Published
2018

90. Long-term follow-up of patients (pts) with relapsed or refractory (r/r) follicular lymphoma (FL) treated with copanlisib.

Author

Leppä, Sirpa, primary, Santoro, Armando, additional, Demeter, Judit, additional, Follows, George, additional, Lenz, Georg, additional, Kim, Won Seog, additional, Mollica, Luigina, additional, Nagler, Arnon, additional, Diong, Colin Phipps, additional, Provencio, Mariano, additional, Stevens, Don A., additional, Trevarthen, David R., additional, Wang, MingLu, additional, Wirtz, Oliver, additional, Miriyala, Ashok, additional, Garcia Vargas, Jose, additional, Childs, Barrett H., additional, Zinzani, Pier Luigi, additional, and Dreyling, Martin H., additional

Published
2019
Full Text
View/download PDF

91. Immunogenomic landscape of hematological malignancies

Author

Dufva, Olli, primary, Pölönen, Petri, additional, Brück, Oscar, additional, Keränen, Mikko, additional, Mehtonen, Juha, additional, Kumar, Ashwini, additional, Heckman, Caroline, additional, Siitonen, Sanna, additional, Granberg, Kirsi, additional, Leivonen, Suvi-Katri, additional, Meriranta, Leo, additional, Leppä, Sirpa, additional, Nykter, Matti, additional, Lohi, Olli, additional, Heinäniemi, Merja, additional, and Mustjoki, Satu, additional

Published
2019
Full Text
View/download PDF

93. Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Author

Dreyling, Martin, primary, Santoro, Armando, additional, Mollica, Luigina, additional, Leppä, Sirpa, additional, Follows, George A, additional, Lenz, Georg, additional, Kim, Won Seog, additional, Nagler, Arnon, additional, Panayiotidis, Panayiotis, additional, Demeter, Judit, additional, Özcan, Muhit, additional, Kosinova, Marina, additional, Bouabdallah, Krimo, additional, Morschhauser, Franck, additional, Stevens, Don, additional, Trevarthen, David, additional, Rodrigues, Liana, additional, Hiemeyer, Florian, additional, Wang, MingLu, additional, Garcia-Vargas, Jose, additional, Childs, Barrett H., additional, and Zinzani, Pier Luigi, additional

Published
2018
Full Text
View/download PDF

94. Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Author

d'Amore, Francesco, primary, Leppä, Sirpa, additional, Silva, Maria Gomes da, additional, Relander, Thomas, additional, Lauritzsen, Grete Fossum, additional, Brown, Peter De Nully, additional, Pezzutto, Antonio, additional, Doorduijn, Jeanette K., additional, Weidmann, Eckhart, additional, van Gelder, Michel, additional, Hoof, Achiel Van, additional, Christiansen, Ilse, additional, Fagerli, Unn Merete, additional, Hagberg, Hans, additional, Lugtenburg, P.J., additional, Walewski, Jan, additional, Wu, Ka Lung, additional, Demuynck, Hilde Maria, additional, Fijnheer, Rob, additional, Christensen, Jacob H., additional, Jankovská, Milada, additional, Josefsson, Pär L., additional, Kluin-Nelemans, Hanneke, additional, Mariz, Jose Mario, additional, Merup, Mats A., additional, Noesslinger, Thomas, additional, Van Den Neste, Eric, additional, Zijlstra, Josée M, additional, Hopfinger, Georg, additional, Prochazka, VIT, additional, Jantunen, Esa, additional, Boudova, Ludmila, additional, Cabecadas, Jose, additional, Chott, Andreas, additional, Delabie, Jan M.A., additional, de Leval, Laurence, additional, Diepstra, Arjan, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Noergaard, Peter, additional, Rosenwald, Andreas, additional, Rymkiewicz, Grzegorz, additional, Sundström, Christer, additional, Truemper, Lorenz, additional, Wulf, Gerald, additional, Chong, Lauren, additional, Bouska, Alyssa, additional, Smith, Lynette, additional, Gisselbrecht, Christian, additional, Ziepert, Marita, additional, Loeffler, Markus, additional, Liestol, Knut, additional, Steidl, Christian, additional, Gascoyne, Randy D., additional, Scott, David W., additional, Altmann, Bettina, additional, Iqbal, Javeed, additional, Chan, Wing C, additional, and Toldbod, Helle, additional

Published
2018
Full Text
View/download PDF

95. Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Author

Zinzani, Pier Luigi, primary, Santoro, Armando, additional, Mollica, Luigina, additional, Leppä, Sirpa, additional, Follows, George A, additional, Lenz, Georg, additional, Kim, Won Seog, additional, Nagler, Arnon, additional, Panayiotidis, Panayiotis, additional, Demeter, Judit, additional, Morschhauser, Franck, additional, Rodrigues, Liana, additional, Reeves, John, additional, Hiemeyer, Florian, additional, Miriyala, Ashok, additional, Garcia-Vargas, Jose, additional, Childs, Barrett H., additional, and Dreyling, Martin H., additional

Published
2018
Full Text
View/download PDF

97. The DLBCL90 gene‐expression assay identifies double‐hit lymphomas with high sensitivity in patients from two phase II clinical trials with high‐risk diffuse large B‐cell lymphoma.

Author

Isaksen, Kathrine T., Beiske, Klaus, Smeland, Erlend B., Jørgensen, Judit, Brodtkorb, Marianne, Myklebust, June Helen, Jerkeman, Mats, Meriranta, Leo, Karjalainen‐Lindsberg, Marja‐Liisa, Leppä, Sirpa, Scott, David W., Holte, Harald, and Blaker, Yngvild Nuvin

Published
2021
Full Text
View/download PDF

98. Th1/2 Immune Response Signature Predicts Outcome after Dose-Dense Immunochemotherapy in Patients with High Risk Diffuse Large B-Cell Lymphoma – Results from Nordic Lymphoma Group Trials

Author

M, Autio, Jørgensen, Judit Meszaros, SK, Leivonen, ML, arjalainen-Lindsberg, Beiske, Klaus, and Leppä, Sirpa

Abstract

Introduction: Despite better therapeutic options and improved survival of diffuse large B-cell lymphoma (DLBCL), 30-40% of the patients still relapse and have dismal prognosis. Recently, the impact of genomic aberrations, allowing lymphoma cells to escape immune recognition on DLBCL pathogenesis has been recognized. However, whether immune related signatures could be used as determinants for treatment outcome has not been rigorously evaluated. Here, our aim was to elucidate the immunologic characteristics of the tumor microenvironment, and associate the findings with outcome in patients with high-risk DLBCL.Patients and methods: We specifically examined gene expression in the tumor microenvironment, using RNA isolated from formalin fixed paraffin-embedded (FFPE) tumor samples from 81 patients with DLBCL. Gene expression analysis was conducted on the NanoString nCounter gene expression platform using a 770-gene PanCancer Immune panel. The predictive impact of the gene expression signatures was assessed using a cohort of 65 high risk DLBCL patients enrolled in the Nordic CHIC trial (Leppä et al., 2016). The findings were validated using exon array data from an independent cohort of 38 high risk DLBCL patients treated in the Nordic CRY-04 trial (Holte et al., 2013; Leivonen et al., 2017a). In both trials, the patients received dose-dense immunochemotherapy (R-CHOEP-14) and systemic central nervous system prophylaxis (HD-Mtx and HD-Ara-C).Results: Unsupervised hierarchical clustering revealed three major clusters of genes with differential expression between the patients. The clusters were enriched for the genes related to focal adhesion and extracellular matrix (ECM) receptor interactions (eg. COL3A1, ITGA, ITGB, VEGFC, VEGFA, PDGFRB, PDGFC, FN1), T/NK-cell signaling (eg. ICAM1, CD3, CD4, CD8 GZMB, ITGB2), and type 1/2 immune responses (eg. IL4, IFNL1, IFNL2, IL13, IL24). Interestingly, type 1/2 immune response signature correlated with survival. In the CHIC cohort, the group of patients (n=10) with high expression of type 1/2 immune response signature genes had a 4-year PFS of 60% in comparison to 91% for those (n=55) with low expression (p=0.021). The corresponding 4 y OS rates were 64% vs 90% (p=ns). The risk of progression was 4.0 fold higher for the patients with high expression of type 1/2 immune response signature genes (95% CI 1.120-14.280, p=0.033). No differences were observed in sex, age, stage, IPI scores, or molecular subgroups between the low and high type 1/2 immune response subgroups. The prognostic impact of the signature was confirmed in the CRY-04 exon array cohort (4-y PFS; 46% vs 80%, p = 0.021, 4-y OS 62% vs 88%; p = 0.014). In the CRY-04 cohort, the risk of progression was 3.6 fold (95% CI 1.13-11.20, p=0.030) and death 4.8 fold (95% CI 1.20-19.26, p=0.027) higher for the group of patients with high expression of the type 1/2 immune response signature genes. In contrast to our data on primary testicular lymphomas (PTLs) (Leivonen et al., 2017b), T/NK cell signature did not correlate with outcome in either of the trial cohorts. Correspondingly, type 1/2 immune signature was not associated with outcome in the cohorts of PTL or DLBCL patients treated with conventional R-CHOP regimen.Conclusion: Our data suggest that immune related signatures exhibit treatment-specific roles in diffuse large B-cell lymphoma. For the high risk DLBCL patients treated with dose-dense immunochemotherapy, high expression of type 1/2 immune response signature genes predicts a poor outcome. A detailed characterization of immune cell composition in the tumor microenvironment and its impact on survival is ongoing.

Published
2017

99. Dose-dense chemoimmunotherapy and CNS prophylaxis in patients with high-risk DLBCL: a comparison of Nordic CRY-04 and CHIC studies

Author

Leppä, Sirpa, Jørgensen, Judit Meszaros, Brown, Peter De Nully, Larsen, Thomas Stauffer, Munksgaard, Lars, Janes, Robert R., Mannisto, S, K, vasala, M, Maisenholder, Meyer, P, Jerkeman, Mats, M, Björkholm, Fluge, Øystein, Jyrkkiö, Sirkku, Pedersen, L.M., Eriksson, M, and Holte, H

Abstract

Background: Survival of patients with high-risk diffuse large B-cell lymphoma (DLBCL) is suboptimal, and the risk of central nervous system (CNS) progression relatively high. We investigated the efficacy of dose-dense chemoimmunotherapy and systemic CNS prophylaxis in two completed Nordic trials including patients less than 65 years with high-risk DLBCL. We combined individual patient data from these studies to compare clinical outcome and prognostic factors in patients treated with CNS prophylaxis given in the beginning (CHIC) vs at the end (CRY-04) of therapy. Patients and methods: Inclusion criteria were age 18-65 years, primary DLBCL or grade 3 follicular lymphoma without signs of CNS involvement, WHO performance score 0-3, age adjusted International Prognostic Index (aaIPI 2-3) and/or involvement of anatomical sites associated with an increased risk for CNS recurrence (e.g. testis, facial sinuses, orbita). In CRY-04, six courses of R-CHOEP14 were followed by HD-Mtx and HD-Ara-C. In CHIC, treatment consisted of two courses of HD-Mtx in combination with R-CHOP14, followed by four courses of R-CHOEP14 and one course of R-HD-AraC. In addition, liposomal AraC was administered intrathecally at courses 1, 3 and 5. Primary end points were failure free survival (FFS; disease progression, discontinuation of protocolled therapy due to toxicity, death from any cause) at three years and CNS progression rate at 1,5 years. Secondary endpoints included progression free survival (PFS; disease progression or death from any cause) and overall survival (OS) at three years. Results: Among 303 patients enrolled in the trials (CRY-04, n=160 and CHIC, n=143), 295 (CRY-04, n=154 and CHIC, n=139) met inclusion criteria and were evaluable for baseline characteristics and primary endpoints. Median age (54 and 56 years, p=0.222), male/female ratio, stage, and aaIPI scores were comparable in the two cohorts. Three-year FFS was 63 % in CRY-04 and 77% in CHIC (p=0.018) after a median follow-up of 5 and 3 years, respectively. Cumulative incidence rates of CNS progression were 5.0% and 2.4% (p=0.22), and three-year OS 80% and 86% (p=0.508), respectively. Treatment in the CHIC reduced the risk of systemic progression (aaIPI adjusted RR=0.484, 95%CI 0.300-0.782, p=0.003). PFS benefit with CHIC vs CRY-04 was observed across pre-specified subgroups, and particularly in patients < 60 years old (p=0.007), with low proliferation index (Ki67 expression

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results